Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody - Fierce Biotech

Roche is paying oncology-focused Simcere Zaiming $75 million upfront for global rights to a preclinical trispecific antibody targeting B-cell-mediated diseases. | Roche is paying oncology-focused Simcere Zaiming $75 million upfront for global rights to a prec…